Clinical Trials Logo

Leiomyosarcoma clinical trials

View clinical trials related to Leiomyosarcoma.

Filter by:

NCT ID: NCT03810976 Recruiting - Sarcoma Clinical Trials

A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma

Start date: March 27, 2018
Phase: Phase 2
Study type: Interventional

The eribulin, a microtubule-dynamics inhibitor was approved for specific subtypes of STS. Eribulin demonstrated significantly better OS compared to dacarbazine in previously treated patients with liposarcoma and leiomyosarcoma and approved as standard treatment. However, the median progression free survival (PFS) and response rate (RR) was similar for both groups which remains modest outcome of 2.6 months of PFS and 4% of RR. Therefore, to improve antitumor activity, further combination strategy is strongly warranted. Based on the previous studies, investigators suggest phase II trial of eribulin and gemcitabine combination in previously treated patients with unresectable, advanced, or metastatic leiomyosarcoma or liposarcoma.

NCT ID: NCT03773510 Not yet recruiting - Leiomyosarcoma Clinical Trials

Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin

Start date: February 28, 2019
Phase: Phase 3
Study type: Interventional

Two arm, randomized, open-label study, to determine the best time to secondary resistance between responding patients who discontinue treatment and resumed Trabectedin at the time of progression versus patients who continued treatment until progression. T

NCT ID: NCT03761095 Not yet recruiting - Leiomyosarcoma Clinical Trials

A Study of PTC596 in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)

Start date: February 27, 2019
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to determine the maximum tolerated dose (MTD) and overall safety profile of PTC596 in combination with dacarbazine for the treatment of advanced LMS. This study will employ the time-to-event continual reassessment method (TITE-CRM) for dose finding. Treatment will be initiated at dose level 2 (DL2) (Dacarbazine 1000 milligrams per square meter [mg/m^2] intravenously (IV) every 21 days in combination with PTC596 200 milligrams [mg] orally twice weekly) for the first participant. This dose level represents the investigator's best assessment of the MTD based on available toxicity data for both agents. For subsequent participants, the dose level at which treatment is initiated will be selected based on the TITE-CRM using the most up to date dose-limiting toxicity (DLT) information from all participants previously treated. Treatment will continue for each participant until evidence of unacceptable toxicity, disease progression, or treatment discontinuation for another reason (study intervention discontinuation and participant discontinuation/withdrawal).

NCT ID: NCT03718091 Recruiting - Solid Tumor Clinical Trials

M6620 (VX-970) in Selected Solid Tumors

Start date: January 8, 2019
Phase: Phase 2
Study type: Interventional

This research study is studying a drug called M6620 as a possible treatment for advanced solid tumor.

NCT ID: NCT03670069 Not yet recruiting - Clinical trials for Metastatic Leiomyosarcoma

Itacitinib in Treating Participants With Refractory Metastatic/Advanced Soft Tissue Sarcomas

Start date: February 12, 2019
Phase: Phase 1
Study type: Interventional

This pilot phase I trial studies how well itacitinib works in treating participants with soft tissue sarcomas that do not respond to treatment and have spread to other parts of the body. Itacitinib may cause changes in the immune system and the body's immune response to cancer, which may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03651375 Recruiting - Sarcoma Clinical Trials

Hypofractionated Radiotherapy With Sequential Chemotherapy in Primary Unresectable or Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall

Start date: February 11, 2017
Phase: Phase 2
Study type: Interventional

After a screening, which consists of biopsy, physical examination, initial diffusion-weighted magnetic resonance imaging (DWI-MRI), body computed tomography (CT) scan, blood tests and case analysis on Multidisciplinary Team (MDT) meeting, a patient will receive the first course of chemotherapy - doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm (AI regimen) with prophylactic mesna. Then a patient will be irradiated 5x5 Gy and after radiotherapy he or she will receive two courses of AI within 4-6 weeks, depending on the tolerance. Then the response analysis in DWI-MRI and toxicity assessment and will be performed. On the second MDT meeting, a final decision about resectability of the tumor will be made. In case of resectability, a patient will be referred to surgery.

NCT ID: NCT03536780 Not yet recruiting - Clinical trials for Leiomyosarcoma Metastatic

Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment

Start date: July 2018
Phase: Phase 2
Study type: Interventional

A Phase 2 trial of avelumab plus gemcitabine in advanced leiomyosarcoma as a second line treatment

NCT ID: NCT03526679 Recruiting - Advanced Cancer Clinical Trials

Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma

Start date: July 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study is designed to test the safety and efficacy of the combination of lenvatinib, a drug that can inhibit the growth of supplying vessels around the tumors, and eribulin, a chemotherapy drug that targets the cancer cell during mitosis, in inoperable or metastatic adipocytic sarcoma and leiomyosarcoma.

NCT ID: NCT03509207 Recruiting - Leiomyosarcoma Clinical Trials

Vorinostat (SAHA) in Uterine Sarcoma

Start date: December 14, 2017
Phase: Phase 2
Study type: Interventional

Uterine sarcomas are rare tumors with a poor prognosis. The main purpose of this phase II proof-of-principle- pilot study is to test the efficacy of the hydroxamic acid-based Histone deacetylase inhibitor (HDACI) Vorinostat (SAHA) as monotherapy in patients with HDAC-positive, progressive, metastatic uterine sarcomas and mixed epithelial and mesenchymal tumors after prior anti-proliferative therapy.

NCT ID: NCT03437070 Recruiting - Leiomyosarcoma Clinical Trials

Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma

Start date: February 2019
Phase: Phase 1
Study type: Interventional

This study seeks to determine if addition of trabectedin (T) to combination doxorubicin (D) and olaratumab (O), is feasible and tolerable with antitumor activity in metastatic or recurrent Leiomyosarcomas (LMS) patients who have limited therapeutic options.